Novo Nordisk CEO: Don't scapegoat pricing pressure. Better drugs grow anyway
admin 9th August 2017 Uncategorised 0Novo Nordisk, like its rival drugmakers in diabetes, is still grappling with the pricing pressure that’s assaulted the business for a couple of years. That’s the bad news. The good? Pricing isn’t the be-all of growth. It’s portfolio.
More: Novo Nordisk CEO: Don't scapegoat pricing pressure. Better drugs grow anyway
Source: fierce